News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clinical Data on TetraLogic Pharmaceuticals’ Smac Mimetic Birinapant to be Presented at American Society of Clinical Oncology


5/22/2013 7:03:25 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced that data from two clinical studies investigating its lead Smac mimetic drug candidate birinapant (formerly TL32711) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31 – June 4, 2013 in Chicago, IL. Birinapant is in clinical trials for solid tumors and hematological malignancies.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES